ClinicalTrials.govpublic full text
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
metastatic pancreatic ductal adenocarcinoma, homologous recombination deficiency (hrd), pembrolizumab, olaparib (polar), 20-481, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 908639
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.